1. Mabuchi S, Sugiyama T and Kimura T: Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol 27: e31, 2016.
2. Ishibashi H, Takano M, Miyamoto M, et al.: Role of endometriosis as a prognostic factor for post-progression survival in ovarian clear cell carcinoma. Mol Clin Oncol 7: 1027-1031, 2017.
3. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF and Gershenson DM: Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105: 404-408, 2007.
4. Takano M, Sugiyama T, Yaegashi N, et al.: Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 18: 937-942, 2008.
5. Network CGAR: Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
6. Ho ES, Lai CR, Hsieh YT, et al.: p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 80: 189-193, 2001.
7. Gurung A, Hung T, Morin J and Gilks CB: Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology 62: 59-70, 2013.
8. Kuo KT, Mao TL, Jones S, et al.: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597-1601, 2009.
9. Anglesio MS, Wiegand KC, Melnyk N, et al.: Type-specific cell line models for type-specific ovarian cancer research. PLoS One 8: e72162, 2013.
10. Wiegand KC, Shah SP, Al-Agha OM, et al.: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543, 2010.
11. Jones S, Wang TL, Shih Ie M, et al.: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231, 2010.
12. Margueron R, Trojer P and Reinberg D: The key to development: interpreting the histone code? Curr Opin Genet Dev 15: 163-176, 2005.
13. Varier RA and Timmers HT: Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta 1815: 75-89, 2011.
14. Hamamoto R, Saloura V and Nakamura Y: Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nat Rev Cancer 15: 110-124, 2015.
15. Sone K, Piao L, Nakakido M, et al.: Critical role of lysine 134 methylation on histone H2AX for gamma-H2AX production and DNA repair. Nat Commun 5: 5691, 2014.
16. Oki S, Sone K, Oda K, et al.: Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer. Oncotarget 8: 40402-40411, 2017.
17. Bennett RL, Swaroop A, Troche C and Licht JD: The Role of Nuclear ReceptorBinding SET Domain Family Histone Lysine Methyltransferases in Cancer. Cold Spring Harb Perspect Med 72017.
18. Battaglia A, Carey JC and South ST: Wolf-Hirschhorn syndrome: A review and update. Am J Med Genet C Semin Med Genet 169: 216-223, 2015.
19. Toyokawa G, Cho HS, Masuda K, et al.: Histone lysine methyltransferase WolfHirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia 13: 887-898, 2011.
20. Zhou P, Wu LL, Wu KM, et al.: Overexpression of MMSET is correlation with poor prognosis in hepatocellular carcinoma. Pathol Oncol Res 19: 303-309, 2013.
21. Hudlebusch HR, Santoni-Rugiu E, Simon R, et al.: The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin Cancer Res 17: 2919-2933, 2011.
22. Hudlebusch HR, Skotte J, Santoni-Rugiu E, et al.: MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Res 71: 4226-4235, 2011.
23. Yang S, Zhang Y, Meng F, et al.: Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma. Biomarkers 18: 257-263, 2013.
24. Xiao M, Yang S, Chen J, et al.: Overexpression of MMSET in endometrial cancer: a clinicopathologic study. J Surg Oncol 107: 428-432, 2013.
25. Wu J, Luo M, Duan Z, et al.: WHSC1 acts as a prognostic indicator and functions as an oncogene in cervical cancer. Onco Targets Ther 12: 4683-4690, 2019.
26. Yin Z, Sun Y, Ge S and Sun J: Epigenetic activation of WHSC1 functions as an oncogene and is associated with poor prognosis in cervical cancer. Oncol Rep 37: 2286- 2294, 2017.
27. Cao R, Wang L, Wang H, et al.: Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298: 1039-1043, 2002.
28. Varambally S, Dhanasekaran SM, Zhou M, et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
29. Knutson SK, Wigle TJ, Warholic NM, et al.: A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8: 890-896, 2012.
30. Wu C, Jin X, Yang J, et al.: Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer. Oncotarget 7: 3440-3452, 2016.
31. McCabe MT, Ott HM, Ganji G, et al.: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108-112, 2012.
32. Bitler BG, Aird KM, Garipov A, et al.: Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 21: 231-238, 2015.
33. Asangani IA, Ateeq B, Cao Q, et al.: Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell 49: 80-93, 2013.
34. Popovic R, Martinez-Garcia E, Giannopoulou EG, et al.: Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet 10: e1004566, 2014.
35. 日本がん分子標的学会: News Letter.第 23-1 号,2019.
36. Burger RA, Brady MF, Bookman MA, et al.: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483, 2011.
37. Perren TJ, Swart AM, Pfisterer J, et al.: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-2496, 2011.
38. Aghajanian C, Blank SV, Goff BA, et al.: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30: 2039-2045, 2012.
39. Pujade-Lauraine E, Hilpert F, Weber B, et al.: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32: 1302-1308, 2014.
40. Pujade-Lauraine E, Ledermann JA, Selle F, et al.: Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebocontrolled, phase 3 trial. Lancet Oncol 18: 1274-1284, 2017.
41. Friedlander M, Gebski V, Gibbs E, et al.: Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol 19: 1126-1134, 2018.
42. Ledermann J, Harter P and Gourley C: Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 16: e158, 2015.
43. 日本婦人科腫瘍学会: 卵巣癌治療ガイドライン 2015 年版.2015.
44. Hamamoto R, Furukawa Y, Morita M, et al.: SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6: 731-740, 2004.
45. Takawa M, Masuda K, Kunizaki M, et al.: Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102: 1298-1305, 2011.
46. Cho HS, Hayami S, Toyokawa G, et al.: RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 14: 476- 486, 2012.
47. Salz T, Li G, Kaye F, Zhou L, Qiu Y and Huang S: hSETD1A regulates Wnt target genes and controls tumor growth of colorectal cancer cells. Cancer Res 74: 775- 786, 2014.
48. Cho HS, Kelly JD, Hayami S, et al.: Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia 13: 676-684, 2011.
49. Ikeda Y, Oda K, Ishihara H, et al.: Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy. Br J Cancer 113: 1477-1483, 2015.
50. Fukuda T, Oda K, Wada-Hiraike O, et al.: The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition. Gynecol Oncol 137: 538-545, 2015.
51. Chuwa AH, Sone K, Oda K, et al.: Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. Gynecol Oncol 141: 564-569, 2016.
52. Kashiyama T, Oda K, Ikeda Y, et al.: Antitumor activity and induction of TP53- dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One 9: e87220, 2014.
53. Miyasaka A, Oda K, Ikeda Y, et al.: Anti-tumor activity of olaparib, a poly (ADPribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer 14: 179, 2014.
54. Colon-Diaz M, Baez-Vega P, Garcia M, et al.: HDAC1 and HDAC2 are differentially expressed in endometriosis. Reprod Sci 19: 483-492, 2012.
55. Monteiro JB, Colon-Diaz M, Garcia M, et al.: Endometriosis is characterized by a distinct pattern of histone 3 and histone 4 lysine modifications. Reprod Sci 21: 305-318, 2014.
56. Colon-Caraballo M, Torres-Reveron A, Soto-Vargas JL, et al.: Effects of histone methyltransferase inhibition in endometriosis. Biol Reprod 99: 293-307, 2018.
57. Saloura V, Cho HS, Kiyotani K, et al.: WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck. Mol Cancer Res 13: 293-304, 2015.
58. Li N, Xue W, Yuan H, et al.: AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. J Clin Invest 127: 1284- 1302, 2017.
59. Evans DL, Zhang H, Ham H, et al.: MMSET is dynamically regulated during cell-cycle progression and promotes normal DNA replication. Cell Cycle 15: 95-105, 2016.
60. Aytes A, Giacobbe A, Mitrofanova A, et al.: NSD2 is a conserved driver of metastatic prostate cancer progression. Nat Commun 9: 5201, 2018.
61. Morrison MJ, Boriack-Sjodin PA, Swinger KK, et al.: Identification of a peptide inhibitor for the histone methyltransferase WHSC1. PLoS One 13: e0197082, 2018.